This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

MannKind's Diabetes Device Under More Clouds

VALENCIA, Calif. ( TheStreet) -- Common sense went AWOL during MannKind's (MNKD) conference call Tuesday morning.

MannKind officials, including billionaire inventor and CEO Al Mann, spent an hour on the phone with investors, trying to put a positive spin on Monday's decision by the U.S. Food and Drug Administration to delay approval of Afrezza, the company's inhaled insulin device for diabetes.

Yet, the more Mann and his underlings spoke, the more confusing and nonsensical the call became. Doubts and questions about the approvability and commercial viability of MannKind's Afrezza device seem more pronounced today than they were Monday.

MannKind's shares closed Monday at $7.89 but rose about 12% in Tuesday's pre-market trading session in advance of the conference call. By the call's conclusion around 10 am, the stock sunk into the red, down 4% to $7.57 in recent trading.

In January, MannKind said FDA was forced to delay the approval decision for Afrezza because the agency has mistakenly forgot to complete an inspection of the European facility that makes the insulin used in Afrezza.

Yet on Tuesday's call, MannKind admitted that the FDA inspection of that insulin plant was still not complete and was scheduled for next week. Management couldn't explain how or why FDA chose issue to its complete response letter for Afrezza on Friday with the manufacturing plant inspection still outstanding.

MannKind management confirmed FDA is questioning the "clinical utility" of Afrezza. The company is required to submit data to FDA showing how Afrezza is to be used, by which diabetes patients in particular, and when the device's use is best.

MannKind insists that no new clinical trials will be needed to compile this information for FDA, yet the company acknowledges that its original data package containing this type of information was not robust enough to assuage the FDA's concerns.

Under questioning, the company also admitted that one reason FDA wants additional data on Afrezza's clinical utility is because Afrezza's use, if it's ever approved, will be restricted to certain types of diabetes patients.

The FDA has told MannKind that Afrezza will require a risk-management plan to better inform patients of the risks of the device. This might include a requirement that doctors test the lung function of patients using Afrezza, according to MannKind's 10-K filed with the Securities and Exchange Commission.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
MNKD $0.94 0.71%
AAPL $93.44 -0.88%
FB $100.12 -0.87%
GOOG $674.33 -1.40%
TSLA $156.52 8.90%


Chart of I:DJI
DOW 15,632.24 -282.50 -1.78%
S&P 500 1,825.47 -26.39 -1.43%
NASDAQ 4,237.9050 -45.6870 -1.07%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs